PMID- 34860898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211206
IS  - 8755-1225 (Print)
IS  - 1549-4810 (Electronic)
IS  - 1549-4810 (Linking)
VI  - 30
IP  - 4
DP  - 2014 Aug
TI  - Weekly Exenatide Therapy: A Real-World Comparison of Incretin Therapies.
PG  - 118-124
LID - 10.1177/8755122513518189 [doi]
AB  - Background: Traditional diabetes therapies have been associated with weight gain, 
      hypoglycemia, and/or high secondary failure rates. Glucagon-like peptide-1 
      (GLP-1) analog use is associated with a minimal risk of hypoglycemia, a 
      persistent average weight loss of 2 to 3 kg, and sustained efficacy even after 3 
      years of use. Presently, 3 GLP-1 analogs are commercially available in the United 
      States. Objective: To evaluate the real-world clinical utility of once weekly 
      exenatide in type 2 diabetes mellitus (T2DM) patients who previously received 
      once or twice daily GLP-1 therapy. Methods: In this pre-post observational study, 
      electronic medical records (EMRs) were reviewed to identify patients meeting all 
      study criteria. Data collected included baseline patient demographic information, 
      duration of diabetes, disease states, medications, pertinent laboratory data, 
      blood pressure, height, weight, and reported adverse drug events. Primary 
      (changes in A1C and percentage of patients reporting adverse effects of therapy) 
      and secondary (percentage of patients with A1C of <7% and changes in weight, 
      blood pressure, and lipids) outcomes were evaluated using appropriate statistical 
      analysis. Results: EMRs of 78 patients met all study criteria. Baseline patient 
      demographic information included an average age of 61 +/- 12 years, an average 
      duration of T2DM of 14 +/- 6 years, 59% of patients were male, and 93.6% were 
      Caucasian. The baseline average body mass index was 39 +/- 9.2, and mean A1C was 
      7.47 +/- 1.45%. After a minimum of 3 months (average = 5.6 months) switchover, 
      there were significant decreases in A1C (-0.35%; P = .0067) and weight (-1.6 kg; 
      P = .0151). There were no significant changes in blood pressure or lipid levels. 
      Two patients (2.5%) discontinued once weekly exenatide due to adverse reactions. 
      Conclusion: Once weekly exenatide was generally well tolerated and significantly 
      reduced A1C levels and body weight in patients with T2DM when switched from a 
      shorter-acting GLP-1 analog.
CI  - (c) The Author(s) 2014.
FAU - Micale, Sara J
AU  - Micale SJ
AD  - Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
FAU - Khatounabadi, Shahabodin
AU  - Khatounabadi S
AD  - Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
FAU - Kane, Michael P
AU  - Kane MP
AD  - Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
FAU - Busch, Robert S
AU  - Busch RS
AD  - The Endocrine Group, LLP, Albany, NY, USA.
FAU - Bakst, Gary
AU  - Bakst G
AD  - The Endocrine Group, LLP, Albany, NY, USA.
FAU - Abelseth, Jill M
AU  - Abelseth JM
AD  - The Endocrine Group, LLP, Albany, NY, USA.
FAU - Hamilton, Robert A
AU  - Hamilton RA
AD  - Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20140107
PL  - United States
TA  - J Pharm Technol
JT  - The Journal of pharmacy technology : jPT : official publication of the 
      Association of Pharmacy Technicians
JID - 8504643
PMC - PMC5990137
OTO - NOTNLM
OT  - GLP-1 analog
OT  - diabetes mellitus
OT  - exenatide
OT  - incretin mimetic
OT  - liraglutide
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Michael P. Kane, PharmD, FCCP, BCPS, BCACP, received 
      an investigator-initiated grant from Bristol Myers Squibb Company, makers of 
      Bydureon, for the conduction of this study. Robert S. Busch, MD, has received 
      speaking honoraria from Bristol Myers Squibb. Sara J Micale, PharmD, Shahab 
      Khatounabadi, Gary Bakst, MD, Jill M. Abelseth, MD, and Robert A. Hamilton, 
      PharmD, MPH, report no relevant conflicts of interest.
EDAT- 2014/08/01 00:00
MHDA- 2014/08/01 00:01
PMCR- 2015/01/07
CRDT- 2021/12/03 17:27
PHST- 2021/12/03 17:27 [entrez]
PHST- 2014/08/01 00:00 [pubmed]
PHST- 2014/08/01 00:01 [medline]
PHST- 2015/01/07 00:00 [pmc-release]
AID - 10.1177_8755122513518189 [pii]
AID - 10.1177/8755122513518189 [doi]
PST - ppublish
SO  - J Pharm Technol. 2014 Aug;30(4):118-124. doi: 10.1177/8755122513518189. Epub 2014 
      Jan 7.